Limitations and Pitfalls of FDG-PET/CT in Infection and Inflammation

Ограничения и диагностические ошибки FDG-ПЭТ/КТ при инфекциях и воспалении
Thomas Christian Kwee, Riemer H. J. A. Slart, Andor W.J.M. Glaudemans, Lars Christian Gormsen, Jordy P. Pijl, Pieter H. Nienhuis
2021-07-08

FDG-PET/CTPET imaging limitationsfalse-positive findingsinfectious diseasesinflammatory diseases
White blood cells activated by either a pathogen or as part of a systemic inflammatory disease are characterized by high energy consumption and are therefore taking up the glucose analogue PET tracer FDG avidly. It is therefore not surprising that a steadily growing body of research and clinical reports now supports the use of FDG PET/CT to diagnose a wide range of patients with non-oncological diseases. However, using FDG PET/CT in patients with infectious or inflammatory diseases has some limitations and potential pitfalls that are not necessarily as pronounced in oncology FDG PET/CT. Some of these limitations are of a general nature and related to the laborious acquisition of PET images in patients that are often acutely ill, whereas others are more disease-specific and related to the particular metabolism in some of the organs most commonly affected by infections or inflammatory disease. Both inflammatory and infectious diseases are characterized by a more diffuse and less pathognomonic pattern of FDG uptake than oncology FDG PET/CT and the affected organs also typically have some physiological FDG uptake. In addition, patients referred to PET/CT with suspected infection or inflammation are rarely treatment naïve and may have received varying doses of antibiotics, corticosteroids or other immune-modulating drugs at the time of their examination. Combined, this results in a higher rate of false positive FDG findings and also in some cases a lower sensitivity to detect active disease. In this review, we therefore discuss the limitations and pitfalls of FDG PET/CT to diagnose infections and inflammation taking these issues into consideration. Our review encompasses the most commonly encountered inflammatory and infectious diseases in head and neck, in the cardiovascular system, in the abdominal organs and in the musculoskeletal system. Finally, new developments in the field of PET/CT that may help overcome some of these limitations are briefly highlighted.
1
Acquisition is particularly challenging because patients are often acutely ill, making PET imaging laborious and potentially limiting examination quality.
2
Activated leukocytes avidly accumulate FDG, supporting FDG-PET/CT for evaluating a broad range of infectious and inflammatory diseases.
3
Infection and inflammation typically produce diffuse, less pathognomonic FDG uptake superimposed on physiological uptake, reducing disease-specific interpretability compared with oncology imaging.
4
Prior antibiotics, corticosteroids, or other immune-modulating treatments can reduce sensitivity for active disease and contribute to false-negative findings.
5
The combination of nonspecific uptake patterns, physiological organ activity, and treatment effects increases false-positive findings and can lower sensitivity; emerging PET/CT developments may help mitigate these limitations.

FDG-PET/CT imaging in patients with infectious and inflammatory diseases

Limitations, pitfalls, and diagnostic performance of FDG-PET/CT for detecting infections and inflammation, including false-positive findings and reduced sensitivity

Publication Details
Publication Date
2021-07-08
Journal
Publisher
ISSN
Cited by
245
Access Type
Author Information
Authors
Thomas Christian Kwee
Riemer H. J. A. Slart
Andor W.J.M. Glaudemans
Lars Christian Gormsen
Jordy P. Pijl
Pieter H. Nienhuis
Explore further
Open the scid.ai AI chat with a ready-made request: it will find papers on a similar topic and help build a literature review.
Find similar papers in the chat →
Make a presentation
100%